

AmpliPhi Biosciences Corp
Form SC 13G/A
February 17, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

AmpliPhi Biosciences Corporation
(Name of Issuer)

Common Stock, par value \$0.01 per share
(Title of Class of Securities)

03211P103
(CUSIP Number)

December 31, 2014
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

<input type="checkbox"/>	Rule 13d-1(b)
<input checked="" type="checkbox"/>	Rule 13d-1(c)
<input type="checkbox"/>	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“*Act*”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. **03211P103 13G**

Names of Reporting Persons.

I.R.S. Identification Nos. of above

1. persons (entities only).

RA Capital Management, LLC

Check the Appropriate Box if a

2. Member of a Group (See Instructions)

(a) ..

(b) ..

3. SEC Use Only

4. Citizenship or Place of

Organization **Massachusetts**

Number of	5. Sole Voting Power	0 shares
Shares	6. Shared Voting Power	26,785,712 shares
Beneficially	7. Sole Dispositive Power	0 shares
Owned by	8. Shared Dispositive Power	26,785,712 shares
Each Reporting		
Person With		

Aggregate Amount Beneficially Owned by Each Reporting Person

9. **26,785,712 shares**

Check if the Aggregate Amount in Row (9) Excludes

10. Certain Shares (See Instructions) ..

Percent of Class Represented by Amount in Row (9)

11. **9.7%**

Type of Reporting Person (See Instructions)

12. **IA**

CUSIP No. **03211P103 13G**

Names of
Reporting
Persons.
I.R.S.

1. Identification Nos.
of above persons
(entities only).

Peter Kolchinsky

Check the
Appropriate Box

2. if a Member of a
Group (See
Instructions)
(a) ..
(b) ..

3. SEC Use Only

Citizenship or
Place of
4. Organization **United**
States

Number of	5. Sole Voting Power	0 shares
Shares	6. Shared Voting Power	26,785,712 shares
Beneficially	7. Sole Dispositive Power	0 shares
Owned by	8. Shared Dispositive Power	26,785,712 shares
Each Reporting		
Person With		

Aggregate Amount Beneficially Owned by Each Reporting Person
9. **26,785,712 shares**

Check if the Aggregate Amount in Row (9) Excludes ..
10. Certain Shares (See Instructions)

Percent of Class Represented by Amount in Row (9)

11.

9.7%

Type of Reporting Person (See Instructions)

12.

IN

CUSIP No. **03211P103 13G**

Names of Reporting Persons.
I.R.S. Identification Nos. of
above persons (entities only).
1.

**RA Capital Healthcare
Fund, L.P.**

Check the Appropriate Box if
2. a Member of a Group (See
Instructions)

(a) ..
(b) ..

3. SEC Use Only

4. Citizenship or Place of
Organization **Delaware**

Number of	5. Sole Voting Power	0 shares
Shares	6. Shared Voting Power	21,428,575 shares
Beneficially	7. Sole Dispositive Power	0 shares
Owned by	8. Shared Dispositive Power	21,428,575 shares
Each Reporting		
Person With		

Aggregate Amount Beneficially Owned by Each Reporting Person
9.
21,428,575 shares

Check if the Aggregate Amount in Row (9) Excludes ..
10.
Certain Shares (See Instructions)

Percent of Class Represented by Amount in Row (9)
11.
7.8%

12. Type of Reporting Person (See Instructions)

PN (Limited Partnership)

CUSIP No. **03211P103**

Item 1.

- (a) **Name of Issuer:** AmpliPhi Biosciences Corporation (the “Issuer”).
- (b) **Address of the Issuer’s Principal Executive Offices:** 4870 Sadler Road, Suite 300, Glen Allen, Virginia, 23060.

Item 2.

- (a) **Name of Person Filing:** This joint statement on Schedule 13G is being filed by Peter Kolchinsky, RA Capital Management, LLC (“Capital”), and RA Capital Healthcare Fund, L.P. (the “Fund”). Mr. Kolchinsky, Capital and the Fund are collectively referred to herein as the “Reporting Persons.”
- (b) **Address of Principal Business Office:** The principal business office of the Reporting Persons is c/o RA Capital Management, LLC, 20 Park Plaza, Suite 1200, Boston, MA 02116.
- (c) **Citizenship:** Capital is a Massachusetts limited liability company. The Fund is a Delaware limited partnership. Mr. Kolchinsky is a United States citizen.
- (d) **Title and Class of Securities:** Common stock (“Common Stock”).
- (e) **CUSIP Number:** 03211P103

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned:**

RA Capital Management, LLC – 26,785,712 shares

Peter Kolchinsky – 26,785,712 shares

RA Capital Healthcare Fund, L.P. – 21,428,575 shares

(b) Percent of Class:**

RA Capital Management, LLC – 9.7%

Peter Kolchinsky – 9.7%

RA Capital Healthcare Fund, L.P. – 7.8%

(c) Number of shares as to which such person has:

CUSIP No. **03211P103**

(i) sole power to vote or to direct the vote **

RA Capital Management, LLC - 0 shares

Peter Kolchinsky - 0 shares

RA Capital Healthcare Fund, L.P. - 0 shares

(ii) shared power to vote or to direct the vote**

RA Capital Management, LLC – 26,785,712 shares

Peter Kolchinsky – 26,785,712 shares

RA Capital Healthcare Fund, L.P. – 21,428,575 shares

(iii) sole power to dispose or to direct the disposition of**

RA Capital Management, LLC - 0 shares

Peter Kolchinsky - 0 shares

RA Capital Healthcare Fund, L.P. - 0 shares

(iv) shared power to dispose or to direct the disposition of**

RA Capital Management, LLC – 26,785,712 shares

Peter Kolchinsky – 26,785,712 shares

RA Capital Healthcare Fund, L.P. – 21,428,575 shares

** Shares reported herein for the Reporting Persons represent shares of Common Stock issuable upon the conversion of certain shares of Series B Convertible Preferred Stock (“Series B Shares”) and shares of Common Stock the Reporting Persons have the right to acquire through the exercise of warrants dated June 26, 2013 (“Warrant Shares”) beneficially owned as set forth below. In the aggregate, the Reporting Persons own 2,142,857 Series B Shares convertible into 21,428,570 shares of Common Stock and 5,357,142 Warrant Shares. The Series B Shares and Warrant Shares may not be converted such that the number of shares of Common Stock held by the Reporting Persons and their affiliates after such conversion exceeds 9.99% of the outstanding shares of Common Stock. Shares reported herein for Capital represent (a) the above-referenced shares of Common Stock issuable upon the conversion of certain Series B Shares and exercised Warrant Shares and as reported for the Fund, for which the LLC serves as the sole

general partner, and (b) shares of Common Stock issuable upon the conversion of certain Series B Shares and exercised Warrant Shares held in a separately managed account for which Capital serves as investment adviser. Shares reported herein for Mr. Kolchinsky represent the above-referenced shares of Common Stock issuable upon the conversion of certain Series B Shares and exercised Warrant Shares reported for Capital, for which Mr. Kolchinsky serves as the manager. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

CUSIP No. **03211P103**

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certification:

By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits

¹ Joint Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on March 21, 2014.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 17, 2015

RA CAPITAL MANAGEMENT, LLC

By: /s/ Peter Kolchinsky
Peter Kolchinsky
Manager

PETER KOLCHINSKY

/s/ Peter Kolchinsky

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Management, LLC
General Partner

By: /s/ Peter Kolchinsky
Peter Kolchinsky
Manager